Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma

European Journal of Cancer

Volumn 50, Issue 10, 2014, Pages 1836-1846

  Goto, Hiroki ^a   Kojima, Yuki ^b   Matsuda, Kouki ^a   Kariya, Ryusho ^a   Taura, Manabu ^a   Kuwahara, Kazuhiko ^a   Nagai, Hirokazu ^b   Katano, Harutaka ^c   Okada, Seiji ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

AIDS; CD47; Macrophage; Mouse model; Primary effusion lymphoma

Indexed keywords

CD47 ANTIGEN; SMALL INTERFERING RNA;

ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; DRUG TARGETING; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE EVASION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; TUMOR XENOGRAFT;

AIDS; CD47; MACROPHAGE; MOUSE MODEL; PRIMARY EFFUSION LYMPHOMA;

ADULT; ANIMALS; ANTIBODIES; ANTIGENS, CD47; ANTINEOPLASTIC AGENTS; CELL LINE; COCULTURE TECHNIQUES; DNA-BINDING PROTEINS; GENE KNOCKDOWN TECHNIQUES; HUMANS; JANUS KINASE 3; LYMPHOMA, PRIMARY EFFUSION; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, KNOCKOUT; NEOPLASM INVASIVENESS; PHAGOCYTOSIS; RNA INTERFERENCE; TRANSFECTION; TUMOR ESCAPE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901771670     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.03.004     Document Type: Article

References (39)

1. R.G. Nador, E. Cesarman, and A. Chadburn et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus Blood 88 1996 645 656
2. M.Q. Ansari, D.B. Dawson, and R. Nador et al. Primary body cavity-based AIDS-related lymphomas Am J Clin Pathol 105 1996 221 229
3. E. Cesarman, Y. Chang, P.S. Moore, J.W. Said, and D.M. Knowles Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas N Engl J Med 332 1995 1186 1191
4. S. Uddin, A.R. Hussain, and K.A. Al-Hussein et al. Inhibition of phosphatidylinositol 3′-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells Clin Cancer Res 11 2005 3102 3108
5. S. Uddin, A.R. Hussain, and P.S. Manogaran et al. Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma Oncogene 24 2005 7022 7030
6. A.R. Hussain, S.O. Ahmed, and M. Ahmed et al. Cross-talk between NFkB and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis PLoS One 7 2012 e39945
7. E. Boulanger, L. Gerard, and J. Gabarre et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS J Clin Oncol 23 2005 4372 4380
8. J.M. Vose, B.K. Link, and M.L. Grossbard et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma J Clin Oncol 19 2001 389 397
9. J.M. Vose, B.K. Link, M.L. Grossbard, M. Czuczman, A. Grillo-Lopez, and R.I. Fisher Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma Leuk Lymphoma 46 2005 1569 1573
10. B.D. Cheson, and J.P. Leonard Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma N Engl J Med 359 2008 613 626
11. E.J. Brown, and W.A. Frazier Integrin-associated protein (CD47) and its ligands Trends Cell Biol 11 2001 130 135
12. E. Sick, A. Jeanne, C. Schneider, S. Dedieu, K. Takeda, and L. Martiny CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest Br J Pharmacol 167 2012 1415 1430
13. B.R. Blazar, F.P. Lindberg, and E. Ingulli et al. CD47 (integrin-associated protein) engagement of dendritic cell and macrophage counterreceptors is required to prevent the clearance of donor lymphohematopoietic cells J Exp Med 194 2001 541 549
14. A.N. Barclay, and M.H. Brown The SIRP family of receptors and immune regulation Nat Rev Immunol 6 2006 457 464
15. P.A. Oldenborg, H.D. Gresham, and F.P. Lindberg CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis J Exp Med 193 2001 855 862
16. H. Okazawa, S. Motegi, and N. Ohyama et al. Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system J Immunol 174 2005 2004 2011
17. R. Majeti, M.P. Chao, and A.A. Alizadeh et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells Cell 138 2009 286 299
18. S. Jaiswal, C.H. Jamieson, and W.W. Pang et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis Cell 138 2009 271 285
19. M.P. Chao, A.A. Alizadeh, and C. Tang et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma Cell 142 2010 699 713
20. M.P. Chao, A.A. Alizadeh, and C. Tang et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia Cancer Res 71 2011 1374 1384
21. S.B. Willingham, J.P. Volkmer, and A.J. Gentles et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors Proc Natl Acad Sci U S A 109 2012 6662 6667
22. D. Kim, J. Wang, S.B. Willingham, R. Martin, G. Wernig, and I.L. Weissman Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells Leukemia 26 2012 2538 2545
23. T. Chihara, M. Hashimoto, and A. Osman et al. HIV-1 proteins preferentially activate anti-inflammatory M2-type macrophages J Immunol 188 2012 3620 3627
24. H. Goto, K. Matsuda, and P. Srikoon et al. Potent antitumor activity of zoledronic acid-induced Vgamma9Vdelta2 T cells against primary effusion lymphoma Cancer Lett 331 2013 174 182
25. H. Goto, R. Kariya, and M. Shimamoto et al. Antitumor effect of berberine against primary effusion lymphoma via inhibition of NF-kappaB pathway Cancer Sci 103 2012 775 781
26. V.A. Fadok, D.R. Voelker, P.A. Campbell, J.J. Cohen, D.L. Bratton, and P.M. Henson Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages J Immunol 148 1992 2207 2216
27. P.R. Hoffmann, A.M. de Cathelineau, and C.A. Ogden et al. Phosphatidylserine (PS) induces PS receptor-mediated macropinocytosis and promotes clearance of apoptotic cells J Cell Biol 155 2001 649 659
28. S.J. Gardai, K.A. McPhillips, and S.C. Frasch et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte Cell 123 2005 321 334
29. M.P. Chao, S. Jaiswal, and R. Weissman-Tsukamoto et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47 Sci Transl Med 2 2010 63ra94
30. M. Ito, H. Hiramatsu, and K. Kobayashi et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells Blood 100 2002 3175 3182
31. L.D. Shultz, B.L. Lyons, and L.M. Burzenski et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells J Immunol 174 2005 6477 6489
32. K. Takenaka, T.K. Prasolava, and J.C. Wang et al. Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells Nat Immunol 8 2007 1313 1323
33. T. Yamauchi, K. Takenaka, and S. Urata et al. Polymorphic Sirpa is the genetic determinant for NOD-based mouse lines to achieve efficient human cell engraftment Blood 121 2013 1316 1325
34. C. Parravicini, B. Chandran, and M. Corbellino et al. Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease Am J Pathol 156 2000 743 749
35. M.R. Staudt, Y. Kanan, J.H. Jeong, J.F. Papin, R. Hines-Boykin, and D.P. Dittmer The tumor microenvironment controls primary effusion lymphoma growth in vivo Cancer Res 64 2004 4790 4799
36. K.A. Sarosiek, L.E. Cavallin, and S. Bhatt et al. Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma Proc Natl Acad Sci U S A 107 2010 13069 13074
37. B. Edris, K. Weiskopf, and A.K. Volkmer et al. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma Proc Natl Acad Sci U S A 109 2012 6656 6661
38. F.O. Martinez, S. Gordon, M. Locati, and A. Mantovani Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression J Immunol 177 2006 7303 7311
39. M.P. Chao, C. Tang, R.K. Pachynski, R. Chin, R. Majeti, and I.L. Weissman Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy Blood 118 2011 4890 4901